Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

23.49 +0.04 (+0.17%)
Official Closing Price Updated: 7:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks.
There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are hiding in plain sight. 
Via The Motley Fool
Topics Bonds World Trade
Exposures COVID-19 Debt Markets Tariff
Could Pfizer’s 7.1% Yield Be A Trap?
It’s easy to understand why income investors are interested in Pfizer. With a current yield of 7.1%, it’s one of the highest-yielding stocks in the S&P 500. Let’s dig into the dividend and see whether... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing
Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations and national security concerns. 
Via Benzinga
Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
Kwizda Pharma Adopts CARA Life Sciences Platform for Rapid QMS Implementation with Minimal IT Resources
LONDON - April 30, 2025 - PRLog -- Kwizda Pharma, a division of Kwizda Holding GmbH and a leader in the Austrian healthcare market, has selected the CARA Life Sciences Platform from Generis, leading... 
Via PRLog
Topics Artificial Intelligence
Exposures Artificial Intelligence
Buy Pfizer Stock For A Rebound After Crushing Q1 EPS Expectations?
Via Talk Markets
Earnings Scheduled For April 29, 2025
Via Benzinga
Setting Goals: How to Navigate a Chronic Inflammatory Disease
(BPT) - Content sponsored and provided by Pfizer. Ashley partnered with Pfizer to share her experience living with moderate to severe rheumatoid arthritis (RA). 
Via Brandpoint
Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul
Via The Motley Fool
Topics World Trade
Exposures Tariff
This High-Yield Pharma Stock Looks Like an Incredible Bargain
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?
Via The Motley Fool
Topics World Trade
Exposures Tariff
US Stock Futures Fall After Tuesday Rally, But History Favors Bulls: Markets Rose 9 Of Last 10 Mays, Says Expert
U.S. stock futures are down Wednesday morning, despite major averages ending up on Tuesday, and the S&P 500 and Dow Jones notching their sixth-straight day in the green, the longest streak for the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Market Monitor April 30 ( Honeywell, Pfizer, UP - Spotify, Starbucks DOWN)
Wall Street Climbs as Confidence Dips and Rate Cut Hopes Rise 
Via Chartmill
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Via The Motley Fool
Dow Surges 300 Points Amid Trade Deal Hopes: Greed Index Remains In 'Fear' Zone
The CNN Money Fear and Greed index showed further easing in the overall fear level, while the index remained in the "Fear" zone on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
Via The Motley Fool
Pfizer Could Make ‘Tremendous Investments’ In The US, But Here’s Why It’s Choosing Not To
Pfizer Inc. chief executive Albert Bourla says uncertainty related to higher tariffs on pharmaceutical imports under the Trump administration is discouraging the company from investing in the US. 
Via Talk Markets
Topics Government World Trade
Exposures Political Tariff
Which S&P500 stocks are the most active on Tuesday?
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for... 
Via Chartmill
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market. 
Via Investor's Business Daily
Exploring the top movers within the S&P500 index during today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?
Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and... 
Via Benzinga
Topics Bonds
Exposures Debt Markets
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings
Via Benzinga
Exposures Fossil Fuels
Pfizer's Covid Windfall Shrinks, Expands Cost-Cutting Efforts
Pfizer beats Q1 EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining. 
Via Benzinga
Exposures COVID-19
Pfizer Reports Q1 2025: Revenue Down 8% Y/Y
Pfizer's Q1 2025 results indicate a sound earnings performance, with adjusted EPS surpassing expectations. 
Via Talk Markets
Pfizer Inches Down On Mixed Report As Cost Cuts Boost Earnings
The company also reported light sales, thanks to declining sales of key products like Eliquis and Ibrance. 
Via Investor's Business Daily
Topics Government
Exposures COVID-19 Political Product Safety
Pfizer (NYSE:PFE) Misses Q1 Revenue Estimates
Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 7.8% year on year to $13.72 billion. The company’s full-year revenue guidance... 
Via StockStory
If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today
Things were going great, right until the point when they weren't. 
Via The Motley Fool
Exposures COVID-19
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
From Pfizer Inc.
Via Business Wire
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this... 
Via Benzinga
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting... 
Via Benzinga
Topics Government
Exposures COVID-19 Political Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.